Neuralstem Inc (CUR)

1.18
0.01 0.85
NASDAQ : Health Care
Prev Close 1.17
Open 1.17
Day Low/High 1.14 / 1.30
52 Wk Low/High 0.24 / 1.96
Volume 225.55K
Avg Volume 302.30K
Exchange NASDAQ
Shares Outstanding 15.08M
Market Cap 17.79M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neuralstem Reports Last Subject Out In Phase 2 Trial Of NSI-189 For Major Depressive Disorder

Top Line Results Expected in 3Q 2017

Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical And Business Update

Phase 2 MDD clinical trial results expected in 3Q17, Extended runway of cash into 3Q18

Neuralstem Expands Phase 1 Safety Trial Of NSI-566 Neural Stem Cells In Spinal Injury

Investigating New Patient Cohort with Cervical Injury

A Little Something for Everybody

A Little Something for Everybody

Positives seen for bulls and bears as traders shrug off risk.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Neuralstem Reports Third Quarter 2016 Results

Neuralstem Reports Third Quarter 2016 Results

Provides Business and Clinical Updates

Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits At The Radiation Research Society Annual Meeting

Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits At The Radiation Research Society Annual Meeting

NSI-189 Shows Reversal of Radiation-induced Cognitive Deficits

Neuralstem Presented NSI-189 Preclinical Data In Type 1 And Type 2 Diabetes At The Annual Meeting Of The Diabetic Neuropathy Study Group

Neuralstem Presented NSI-189 Preclinical Data In Type 1 And Type 2 Diabetes At The Annual Meeting Of The Diabetic Neuropathy Study Group

NSI-189 Shows Prevention and Reversal of Diabetic Neuropathies in Mice

Neuralstem Reports Second Quarter 2016 Results and Provides Business And Clinical Updates

Neuralstem Reports Second Quarter 2016 Results and Provides Business And Clinical Updates

Dr. Karl Johe Resigns from Board of Directors; Company Announces Creation of Scientific Policy Committee with Dr. Johe as Chairman

Neuralstem Announces NSI-189 Shows Enhancement Of Long-Term Potentiation In Vitro

Neuralstem Announces NSI-189 Shows Enhancement Of Long-Term Potentiation In Vitro

Data Contribute to Understanding NSI-189 Mechanism of Action